National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Naltrexone / bupropion (Mysimba®) is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥ 18 years) with a BMI of ≥30 kg/m2 (obese) or ≥27 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities.

 

Rapid Review

Commenced Completed Outcome
13/02/2017 28/03/2017 A full pharmacoeconomic Evaluation is Recommended.